1. Current Controversies and Recent Clinical Guidelines for use of Epoetin and Darbepoetin Lukas Wartman, M.D. November 2, 2007

8. ENHANCE Trial Results: Locoregional Progression-free Survival R=0 R=1 or 2 1º XRT

12. Leyland-Jones, B. et al. J Clin Oncol; 23:5960-5972 2005 Fig 1. Epoetin alfa dose adjustments

13. Leyland-Jones, B. et al. J Clin Oncol; 23:5960-5972 2005 Fig 2. Patient disposition (intent-to-treat [ITT] population, N = 939)

14. Leyland-Jones, B. et al. J Clin Oncol; 23:5960-5972 2005 Fig 3. Kaplan-Meier estimate of long-term survival, with convergence of lines about 19 months after randomization (as of January 4, 2003; intent-to-treat [ITT] population, N = 939)

15. Leyland-Jones, B. et al. J Clin Oncol; 23:5960-5972 2005 Fig 4. Mean hemoglobin level (95% CI) over time overall and by 12-month survival status (intent-to-treat [ITT] population, N = 939)

16. Leyland-Jones, B. et al. J Clin Oncol; 23:5960-5972 2005 Fig 5. Time to disease progression (intent-to-treat population, N = 939)

18. Wright, J. R. et al. J Clin Oncol; 25:1027-1032 2007 Fig 1. Consort flow chart

19. Wright, J. R. et al. J Clin Oncol; 25:1027-1032 2007 Fig 2. Overall survival curve from time of random assignment